Currently at all-time peak NRR of 117%.
Guardant Health is above the Healthcare SaaS Public median by +8pp (cell median: 109%)
Guardant Health (GH) is a healthcare saas company at the public stage. As of its most recent disclosure (FY2023-Q4), Guardant Health reported a Net Revenue Retention rate of 117% - a strong result for B2B SaaS at this segment.
Guardant Health is currently at or near its all-time NRR peak.
Within its peer set (healthcare saas companies at public stage in the $25k-$100k acv band), Guardant Health's NRR is above the cell median of 109%. Compare against the full peer cell aggregate for distribution and top performers.
Contract shape and forward-booked revenue.
Health scores, usage, and time-to-value when disclosed.
Logo flow per period (count-side complement to dollar-based NRR).
Revenue, ARR, and team-size denominators for the productivity ratios.
Forward-booked revenue by maturity. Renewal pipeline visibility.
Support tiers: Standard · Premier · Strategic
CS team segments: Oncology · Biopharma · Screening
CSM model: account-named
Education programs: Quest promotional activities
Customer Advisory Board: Yes
Computed from the data above. Shows where value comes from and where leakage hides.
Named CS initiatives across recent disclosures (newest first).
1,000-patient prospective study to evaluate Guardant Reveal performance in predicting cancer recurrence.
"In October 2021, we initiated a 1,000-patient prospective, observational, multi-center study... the ORACLE study"
Post FDA-approval study assessing Shield blood test performance.
"In July 2025, we initiated patient enrollment for the required Shield post FDA-approval study... the SOLAR study"
Migration of existing products to the Smart Platform utilizing methylation technology and InfinityAI engine.
"Our product portfolio is now powered by our Smart Platform... migrated some of our existing products"
Commercial availability of the Shield blood test for colorectal cancer screening following FDA approval.
"In August 2024, our Shield blood test became commercially available in the U.S."
Expanded Shield blood test to include a multi-cancer detection (MCD) results report with a data collection effort.
"In October 2025, we expanded our Shield blood test to include a MCD results report"
Launched nationwide, multi-year collaboration with Quest to expand access to Shield and accelerate screening adoption.
"Launched nationwide, multi-year collaboration with Quest to expand access to Shield and accelerate screening adoption"
Nationwide launch of Shield promotion and EMR connectivity through Quest's sales team and patient service centers.
"Our Quest collaboration launched nationwide in late Q1... Quest national sales team has now started actively promoting"
Launch of an opt-in report for Shield CRC patients covering nine additional cancer types.
"The launch of this initiative establishes a scalable platform for clinical data generation... covers finding across nine"
Challenges acknowledged by management. Useful peer signals - your team is probably not alone.
Ongoing patent infringement suit with TwinStrand Biosciences and University of Washington.
"jury found that the Company willfully infringed... awarded TwinStrand Biosciences and the University of Washington $83.4 million"
Civil investigative demand regarding billing to federally funded health insurance programs.
"received a civil investigative demand... in connection with an investigation under the False Claims Act"
Commercial payers proactively reducing reimbursement amounts or seeking recovery of perceived overpayments.
"commercial payers proactively reduced the amounts they were willing to reimburse for our tests"
Oncologic Drugs Advisory Committee voted against the clinical benefit claim for camizestrant, impacting CDx monitoring.
"Oncologic Drugs Advisory Committee voted six to three against the claim that camizestrant demonstrated benefit"
Current LDT reimbursement rules prevent concurrent ordering of tissue and blood tests.
"the way that LDT is reimbursed, you know, it really is, it's not possible to order them concurrently."
Currently receiving near zero reimbursement for commercial patients for Shield tests.
"We have a tranche of commercial patients, and we're effectively getting paid more or less zero for those."
Curated quotes about customer outcomes, retention, renewals.
"Guardant360 Liquid is resonating incredibly well and is helping to drive greater depth of ordering and increased testing frequency"
"We continue to successfully execute on our long-term vision to support patients throughout their entire cancer journey"
"We're seeing more oncologists than ever before ordering every single month... we're seeing a much higher average of number of 360 tests per month."
"we'd be turning on a lot of the sort of capabilities to be able to pull in subsequent test orders... the number of tests per patient has gone up pretty nicely."
"Reveal for therapy monitoring really bridges to that next Guardant360 test, and we have a very unique platform and portfolio that allows these tests to work together."
"Shield continues to demonstrate a high adherence rate of over 90%, which is one of the key differentiators of Shield."
Side-by-side NRR, customer cohorts, commercial structure, and CS motion.
Guardant Health appears on 4 of our retention leaderboards.
Free to embed on your blog or board deck. Includes a small backlink to cust.co.
Or grab the data: JSON API →
Generate a live retention report against Guardant Health and your full peer cell. Ungated. Downloadable as PDF.